ERBA Diagnostics, Inc.
(NYSE MKT: ERB), a fully integrated in vitro diagnostics company, is pleased to announce ERBA Diagnostics will be exhibiting the full range of products from ERBA Diagnostics group including not only the Autoimmune and Infectious Elisa product lines, but also the new product lines from its Drew Scientific and Jas Diagnostics subsidiaries of hematology and Hb1AC equipment and reagents. ERBA Diagnostics will also be displaying its full line of biochemistry, clinical chemistry and urine analysis products of the parent company, ERBA Diagnostics Mannheim GmbH and group companies in India, Czech Republic, France and Italy.
At this show ERBA Diagnostics will be launching a new generation analyzer for Diabetes testing, Hb-Vario, for the measurement of HbA1c/A2.
Diabetes continues to be one of the major challenges worldwide affecting over 300 million people and increasing rapidly specially in developing countries of the world. By 2030, worldwide over 600 million people are expected to be suffering from diabetes.
The benefits of monitoring A1c values to manage complications from diabetes is well documented in numerous studies. The Hb-Vario is capable of processing up to 10 samples at a time with an assay time of 3.5 minutes per sample. The Hb-Vario can sample from a wide number of sample tubes while the touch-screen software makes the unit extremely easy to use.
Another product being launched is the ERBA Automated Chemistry Analyzer XL-400 with very advanced features and a wide test menu of over 50 analytes. It can test up to 400 tests per hour.
AACC’s Clinical Lab Expo is said to be the largest clinical lab exposition in the world with over 20,000 participants from 100+ countries. Over 700 leading manufacturers exhibit their products in 2000+ booths.
About ERBA Diagnostics, Inc.
ERBA Diagnostics, Inc. (
), headquartered in Miami Lakes, Florida, is a fully integrated in vitro diagnostics company that develops, manufactures and distributes in the United States and internationally, proprietary diagnostic reagents, test kits and instrumentation, primarily for autoimmune and infectious diseases, through its legacy subsidiaries – Diamedix Corporation (U.S.), Delta Biologicals S.r.l. (Europe) and ImmunoVision, Inc. (U.S.) – and through its recently acquired subsidiaries – Drew Scientific, Inc. (U.S.), JAS Diagnostics, Inc. (U.S.) and Drew Scientific Limited Co. (Europe).
Safe Harbor Statement
Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by these forward-looking statements.
These forward-looking statements are based largely on ERBA Diagnostics’ expectations, beliefs and assumptions and on the information currently available it and are subject to a number of risks and uncertainties, including, but not limited to:
the risks and uncertainties relating to the Hb-Vario, including, without limitation, that the Hb-Vario may not perform as expected and that the Hb-Vario may not result in revenue growth or improved operating results for ERBA Diagnostics; the risks and uncertainties relating to the XL-400, including, without limitation, that the XL-400 may not perform as expected and that the XL-400 may not result in revenue growth or improved operating results for ERBA Diagnostics; the risks and uncertainties relating to ERBA Diagnostics’ technological, strategic and business initiatives, including, without limitation, that the Hb-Vario and the XL-400 may not result in achieving an improvement in its financial condition, results of operations or cash flows, that it may not be able to expand its product offerings and market reach and that it may not achieve cost or other advantages from its own manufacture of instrument systems, reagents and test kits; the risks and uncertainties relating to ERBA Diagnostics’ relationships with ERBA Diagnostics Mannheim GmbH and the other affiliates in the ERBA Diagnostics group, including, without limitation, that ERBA Diagnostics may not be able to successfully develop brand recognition and collaboration through the worldwide network of ERBA Diagnostics group companies, that ERBA Diagnostics Mannheim GmbH has voting control of ERBA Diagnostics’ common stock, and that conflicts of interest exist with ERBA Diagnostics Mannheim GmbH and with ERBA Diagnostics’ officers, employees and other directors, including, without limitation, directors that are also executive officers of ERBA Diagnostics Mannheim GmbH; and other economic, competitive, governmental, technological and other risks and factors that may cause results to differ materially from those set forth in the forward-looking statements.
In addition to the risks and uncertainties set forth above, you should consider the economic, competitive, governmental, technological and other risks and factors discussed elsewhere in ERBA Diagnostics’ periodic filings with the Securities and Exchange Commission, including, without limitation, in the section entitled “Risk Factors” in such filings.
Many of these risks, uncertainties and factors are beyond ERBA Diagnostics’ control.